Emmy Verschuren received her PhD from UCL in 2003, following graduate studies with Prof. Nic Jones at ICRF/CRUK in London, and Prof. Gerard Evan at UCSF in San Francisco, investigating oncogenic activities of a herpesvirus cyclin. In 2003, she was awarded a Damon Runyon Fellowship for a postdoc with Dr. Peter Jackson at Stanford University, studying cell cycle control imposed by the Anaphase-Promoting Complex ubiquitin ligase inhibitor Emi1. In 2006, she moved with Peter to Genentech Inc. in South San Francisco, and applied a senescence screen to discover new tumour suppressors. Emmy became a FIMM-EMBL Group Leader in 2009. Since 2011, she acts as the Academic Coordinator of the IMI-JU public-private PREDECT consortium. She is also a European Association of Cancer Research (EACR) representative for young investigators.